Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.
Also in this 8-page issue: NCI closes its Tobacco Intervention Research Clinic, blaming flat budget, slow accrual.
Hope for FDA authority over tobacco products dies in Congress.
Patients urge Medicare to allow an open formulary for cancer treatment.
Promotions at MSKCC: Fuks heads radiation oncology, Pfister named chief of Head & Neck Medical Oncology Service.
Funding opportunities listed.
Trending Stories
- Gynecology’s deadly surprise:
Cancers are frequently missed prior to routine procedures - Amy Reed, physician and patient who “moved mountains” to end widespread use of power morcellation, dies at 44
- Rathmell announces new cancer screening network, new NCI virtual clinical trials office
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- ASCO 2024 special awards go to: Winn, Bhatia, Dale, Siu, Pierce, Kantoff, Newman, Gopal, Mutebi, Feldman, Gorlick, Pietenpol, Abrahm, Giordano, Vaz-Luis
- Weeks before death from sarcoma, Norm Coleman reflected on his career in radiation oncology and addressing health disparities